GAMA
NBIX icon

Graticule Asia Macro Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Graticule Asia Macro Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-100,000
Closed -$3.96M – 75
2016
Q1 		$3.96M Buy
+100,000
New +$3.97M 0.31% 57

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Graticule Asia Macro Advisors's NBIX Position: Q4 2017 in Review

Graticule Asia Macro Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2017, closing a stake of 32,700 shares — an estimated $2M sold.

Graticule Asia Macro Advisors first reported a position in NBIX in Q1 2015 and held it in 5 quarters. The position peaked at $5.35M in Q4 2015. 267 funds tracked by Wall St. Rank hold NBIX as of Q4 2017.

  • Graticule Asia Macro Advisors reported no remaining Neurocrine Biosciences position as of Q4 2017 after selling out during the quarter.
  • Graticule Asia Macro Advisors sold 32,700 Neurocrine Biosciences shares in Q4 2017, an estimated $2M.
  • Graticule Asia Macro Advisors first reported a position in Neurocrine Biosciences in Q1 2015 and held it in 5 quarters.
  • Graticule Asia Macro Advisors's Neurocrine Biosciences position peaked at $5.35M in Q4 2015.
  • 267 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2017.

Based on Graticule Asia Macro Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.